{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:59:23Z","timestamp":1791773963567,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson\u2019s disease (PD) is a chronic neurodegenerative disease of the elderly. Patients suffer from progressive motor and non-motor symptoms. Further, PD patients often present geriatric features like multimorbidity and polypharmacotherapy. A frequent comorbidity of PD patients is diabetes mellitus type two (T2DM). In the last decade growing evidence emerged on the impact of T2DM on PD. Of the present review was to analyze the impact of T2DM on PD incidence and progression in patient cohorts. A systematic review of the literature was performed via PubMed and Google Scholar. Studies on longitudinal PD patient cohorts with at least 10 patients per group were included. The diabetic state of the patient had to be determined. In total, 15 studies were analyzed for this review. According to most of the included studies T2DM increases the risk of developing PD significantly. Disease progression is augmented by T2DM both for motor and cognitive impairments. Some studies also point out a correlation of motor worsening and diabetic status measured by the serum HbA1c level. In relation to biomarkers, PD patients with diabetes have higher neurofilament light chain and Tau level but lower Amyloid beta level. T2DM seems to be a risk factor for the development and progression of PD. PD patients should be screened for T2DM and treatment should be initiated promptly. There is still a lack of knowledge about the molecular mechanisms leading to interactions of these diseases.<\/jats:p>","DOI":"10.1007\/s00702-025-02882-7","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:09:39Z","timestamp":1737612579000},"page":"627-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of diabetes mellitus type two on incidence and progression of Parkinson\u2019s disease: a systematic review of longitudinal patient cohorts"],"prefix":"10.1007","volume":"132","author":[{"given":"Olga","family":"Stockmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-7359","authenticated-orcid":false,"given":"Lan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Greten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chemodanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2882_CR1","volume":"11","author":"Y Aguirre-Vidal","year":"2024","unstructured":"Aguirre-Vidal Y, Montes S, Mota-L\u00f3pez AC, Navarrete-V\u00e1zquez G (2024) Antidiabetic drugs in Parkinson\u2019s disease. Clin Park Relat Disord 11:100265","journal-title":"Clin Park Relat Disord"},{"key":"2882_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664\u20131675","journal-title":"Lancet"},{"key":"2882_CR3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.parkreldis.2014.10.008","volume":"20","author":"NI Bohnen","year":"2014","unstructured":"Bohnen NI, Kotagal V, M\u00fcller MLTM et al (2014) Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20:1394\u20131398","journal-title":"Parkinsonism Relat Disord"},{"key":"2882_CR4","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain 143:3067\u20133076","journal-title":"Brain"},{"key":"2882_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","volume":"78","author":"E Cereda","year":"2012","unstructured":"Cereda E, Barichella M, Cassani E et al (2012) Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology 78:1507\u20131511","journal-title":"Neurology"},{"key":"2882_CR6","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez E, Goldacre R, Pakpoor J et al (2018) Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91:e139\u2013e142","journal-title":"Neurology"},{"key":"2882_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00702-011-0724-4","volume":"119","author":"Y Deng","year":"2012","unstructured":"Deng Y, Zhang Y, Li Y et al (2012) Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J Neural Transm 119:435\u2013441","journal-title":"J Neural Transm"},{"key":"2882_CR8","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/JME-17-0138","volume":"60","author":"HC Denroche","year":"2018","unstructured":"Denroche HC, Verchere CB (2018) IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants. J Mol Endocrinol 60:R57\u2013R75","journal-title":"J Mol Endocrinol"},{"key":"2882_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik DL, Pasquali L, Cnop M (2020) Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol 16:349\u2013362","journal-title":"Nat Rev Endocrinol"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40001-023-01628-z","volume":"29","author":"C Geng","year":"2024","unstructured":"Geng C, Meng K, Zhao B et al (2024) Causal relationships between type 1 diabetes mellitus and Alzheimer\u2019s disease and Parkinson\u2019s disease: a bidirectional two-sample Mendelian randomization study. Eur J Med Res 29:53","journal-title":"Eur J Med Res"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00415-023-11803-1","volume":"270","author":"A Gialluisi","year":"2023","unstructured":"Gialluisi A, De Bartolo MI, Costanzo S et al (2023) Risk and protective factors in Parkinson\u2019s disease: a simultaneous and prospective study with classical statistical and novel machine learning models. J Neurol 270:4487\u20134497","journal-title":"J Neurol"},{"key":"2882_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00702-020-02276-x","volume":"128","author":"S Greten","year":"2021","unstructured":"Greten S, M\u00fcller-Funogea JI, Wegner F et al (2021) Drug safety profiles in geriatric patients with Parkinson\u2019s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna) 128:49\u201360","journal-title":"J Neural Transm (Vienna)"},{"key":"2882_CR13","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1073\/pnas.1610371113","volume":"113","author":"I Horvath","year":"2016","unstructured":"Horvath I, Wittung-Stafshede P (2016) Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson\u2019s disease. Proc Natl Acad Sci U S A 113:12473\u201312477","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2882_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu G, Jousilahti P, Bidel S et al (2007) Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 30:842\u2013847","journal-title":"Diabetes Care"},{"key":"2882_CR15","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1073\/pnas.1500877112","volume":"112","author":"A Kleinridders","year":"2015","unstructured":"Kleinridders A, Cai W, Cappellucci L et al (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A 112:3463\u20133468","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2882_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40266-019-00654-z","volume":"36","author":"M Klietz","year":"2019","unstructured":"Klietz M, Greten S, Wegner F, H\u00f6glinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson\u2019s disease in geriatric patients. Drugs Aging 36:511\u2013530","journal-title":"Drugs Aging"},{"key":"2882_CR17","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3233\/JPD-230104","volume":"14","author":"A K\u00f6nig","year":"2024","unstructured":"K\u00f6nig A, Outeiro TF (2024) Diabetes and Parkinson\u2019s Disease: understanding shared molecular mechanisms. J Parkinsons Dis 14:917\u2013924","journal-title":"J Parkinsons Dis"},{"key":"2882_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550","journal-title":"Pharmacol Res"},{"key":"2882_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","volume":"19","author":"V Kotagal","year":"2013","unstructured":"Kotagal V, Albin RL, M\u00fcller MLTM et al (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19:522\u2013526","journal-title":"Parkinsonism Relat Disord"},{"key":"2882_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-022-00288-z","volume":"11","author":"Y-Q Lv","year":"2022","unstructured":"Lv Y-Q, Yuan L, Sun Y et al (2022) Long-term hyperglycemia aggravates \u03b1-synuclein aggregation and dopaminergic neuronal loss in a Parkinson\u2019s disease mouse model. Transl Neurodegener 11:14","journal-title":"Transl Neurodegener"},{"issue":"2","key":"2882_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/jcm13020561","volume":"13","author":"AS Mai","year":"2024","unstructured":"Mai AS, Tan BJ-W, Sun Q-Y, Tan E-K (2024) Association between Type 1 Diabetes Mellitus and Parkinson\u2019s Disease: a mendelian randomization study. J Clin Med Res 13(2):561. https:\/\/doi.org\/10.3390\/jcm13020561","journal-title":"J Clin Med Res"},{"issue":"18_Supplement","key":"2882_CR22","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1212\/WNL.98.18_supplement.3068","volume":"98","author":"C Malatt","year":"2022","unstructured":"Malatt C, Wu T, Bresee C et al (2022) Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson\u2019s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9\u201311.005). Neurology 98(18_Supplement):3068","journal-title":"Neurology"},{"key":"2882_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345","journal-title":"Lancet Neurol"},{"key":"2882_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C et al (2024) Trial of Lixisenatide in Early Parkinson\u2019s Disease. N Engl J Med 390:1176\u20131185","journal-title":"N Engl J Med"},{"key":"2882_CR25","doi-asserted-by":"publisher","first-page":"20438","DOI":"10.1038\/s41598-020-77409-z","volume":"10","author":"M Mucibabic","year":"2020","unstructured":"Mucibabic M, Steneberg P, Lidh E et al (2020) \u03b1-Synuclein promotes IAPP fibril formation in vitro and \u03b2-cell amyloid formation in vivo in mice. Sci Rep 10:20438","journal-title":"Sci Rep"},{"key":"2882_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","volume":"121","author":"P Nadkarni","year":"2014","unstructured":"Nadkarni P, Chepurny OG, Holz GG (2014) Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci 121:23\u201365","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2882_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214364","volume":"14","author":"P Novak","year":"2019","unstructured":"Novak P, Pimentel Maldonado DA, Novak V (2019) Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS ONE 14:e0214364","journal-title":"PLoS ONE"},{"key":"2882_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120851","volume":"454","author":"K Ogaki","year":"2023","unstructured":"Ogaki K, Fujita H, Nozawa N et al (2023) Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson\u2019s disease. J Neurol Sci 454:120851","journal-title":"J Neurol Sci"},{"key":"2882_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/acn3.51343","volume":"8","author":"R Ou","year":"2021","unstructured":"Ou R, Wei Q, Hou Y et al (2021) Effect of diabetes control status on the progression of Parkinson\u2019s disease: A prospective study. Ann Clin Transl Neurol 8:887\u2013897","journal-title":"Ann Clin Transl Neurol"},{"key":"2882_CR30","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654\u2013e1662","journal-title":"Neurology"},{"key":"2882_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neuroscience.2016.01.020","volume":"318","author":"Y Pang","year":"2016","unstructured":"Pang Y, Lin S, Wright C et al (2016) Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 318:157\u2013165","journal-title":"Neuroscience"},{"key":"2882_CR32","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s00415-022-11496-y","volume":"270","author":"G Pezzoli","year":"2023","unstructured":"Pezzoli G, Cereda E, Amami P et al (2023) Onset and mortality of Parkinson\u2019s disease in relation to type II diabetes. J Neurol 270:1564\u20131572","journal-title":"J Neurol"},{"key":"2882_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/dc19-0760","volume":"43","author":"SY Rhee","year":"2020","unstructured":"Rhee SY, Han K-D, Kwon H et al (2020) Association Between Glycemic Status and the Risk of Parkinson Disease: a Nationwide Population-Based Study. Diabetes Care 43:2169\u20132175","journal-title":"Diabetes Care"},{"issue":"16","key":"2882_CR34","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/nu15163585","volume":"15","author":"VA Ruiz-Pozo","year":"2023","unstructured":"Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S et al (2023) The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson\u2019s Disease Pathogenesis. Nutrients 15(16):3585. https:\/\/doi.org\/10.3390\/nu15163585","journal-title":"Nutrients"},{"key":"2882_CR35","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1212\/01.wnl.0000271883.45010.8a","volume":"69","author":"KC Simon","year":"2007","unstructured":"Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688\u20131695","journal-title":"Neurology"},{"issue":"12","key":"2882_CR36","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.3390\/ijms22126609","volume":"22","author":"I Sirangelo","year":"2021","unstructured":"Sirangelo I, Iannuzzi C (2021) Understanding the Role of Protein Glycation in the Amyloid Aggregation Process. Int J Mol Sci 22(12):6609. https:\/\/doi.org\/10.3390\/ijms22126609","journal-title":"Int J Mol Sci"},{"key":"2882_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","volume":"365","author":"M Stumvoll","year":"2005","unstructured":"Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333\u20131346","journal-title":"Lancet"},{"key":"2882_CR38","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/mds.26734","volume":"31","author":"P Svenningsson","year":"2016","unstructured":"Svenningsson P, Wirdefeldt K, Yin L et al (2016) Reduced incidence of Parkinson\u2019s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord 31:1422\u20131423","journal-title":"Mov Disord"},{"key":"2882_CR39","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/mds.29009","volume":"37","author":"M Uyar","year":"2022","unstructured":"Uyar M, Lezius S, Buhmann C et al (2022) Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson\u2019s Disease (MARK-PD Study). Mov Disord 37:1299\u20131304","journal-title":"Mov Disord"},{"key":"2882_CR40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/NDT.S474584","volume":"20","author":"L Veith Sanches","year":"2024","unstructured":"Veith Sanches L, Greten S, Doll-Lee J et al (2024) SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study. Neuropsychiatr Dis Treat 20:1849\u20131859","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2882_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/brainsci12010089","volume":"12","author":"H von Eichel","year":"2022","unstructured":"von Eichel H, Heine J, Wegner F et al (2022) Neuropsychiatric symptoms in parkinson\u2019s disease patients are associated with reduced health-related quality of life and increased caregiver burden. Brain Sci 12:89. https:\/\/doi.org\/10.3390\/brainsci12010089","journal-title":"Brain Sci"},{"key":"2882_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12974-024-03072-0","volume":"21","author":"M Wang","year":"2024","unstructured":"Wang M, Tian T, Zhou H et al (2024) Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson\u2019s disease through Mfn2-cGAS signaling. J Neuroinflammation 21:81","journal-title":"J Neuroinflammation"},{"key":"2882_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","volume":"34","author":"Q Xu","year":"2011","unstructured":"Xu Q, Park Y, Huang X et al (2011) Diabetes and risk of Parkinson\u2019s disease. Diabetes Care 34:910\u2013915","journal-title":"Diabetes Care"},{"key":"2882_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005921","volume":"96","author":"Y-W Yang","year":"2017","unstructured":"Yang Y-W, Hsieh T-F, Li C-I et al (2017) Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96:e5921","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02882-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:45:20Z","timestamp":1746521120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02882-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02882-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}